Conference Coverage

Promising new therapies for managing Tourette syndrome


 

FROM WCN 2023

Simple and exciting

The new device is “really exciting”, she added. “It’s not invasive and is quite simple to use and could help a lot of people with Tourette syndrome.”

Asked to comment, Alan Carson, MD, consultant neuropsychiatrist and honorary professor of neuropsychiatry, University of Edinburgh, who co-chaired the neuropsychiatry session featuring this presentation, called the device “promising.”

“Deep brain stimulation appears to be very effective but it’s a major procedure, so a simple wearable device seems highly desirable,” Dr. Carson said.

Dr. Joyce also discussed a study on the efficacy of cannabis (nabiximols; Sativex) as an intervention for tic management in males, those with severe tics, and those with comorbid ADHD.

And a new oral medication, ecopipam, a highly selective D1 receptor antagonist, is also raising hopes, said Dr. Joyce, with results from a randomized controlled trial showing the drug significantly improved tics and had few adverse effects.

Dr. Joyce and Dr. Carson report no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Child neurology: Dr. John Bodensteiner considers the path from 1993
MDedge Neurology
More children missing developmental milestones: Survey
MDedge Neurology
‘Brain fitness program’ may aid memory loss, concussion, ADHD
MDedge Neurology
Concussion may not affect IQ in children
MDedge Neurology
Folic acid supplementation for birth defects reaffirmed
MDedge Neurology
Thrombectomy improves outcomes in pediatric stroke
MDedge Neurology
CTE common among young athletes in largest brain donor study
MDedge Neurology
New guidelines for determining brain death released
MDedge Neurology
Are migraine preventives underused in young adults?
MDedge Neurology
New meningococcal vaccine wins FDA approval
MDedge Neurology